Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Short term Debt over the past 6 years, most recently at $13.5 million for Q3 2025.

  • Quarterly results put Short term Debt at $13.5 million for Q3 2025, down 8.34% from a year ago — trailing twelve months through Sep 2025 was $13.5 million (down 8.34% YoY), and the annual figure for FY2024 was $15.0 million, up 206.31%.
  • Short term Debt for Q3 2025 was $13.5 million at Rani Therapeutics Holdings, down from $15.0 million in the prior quarter.
  • Over the last five years, Short term Debt for RANI hit a ceiling of $15.0 million in Q4 2024 and a floor of $30000.0 in Q2 2022.
  • Median Short term Debt over the past 5 years was $4.9 million (2023), compared with a mean of $6.8 million.
  • Biggest five-year swings in Short term Debt: crashed 96.6% in 2022 and later skyrocketed 2121.82% in 2023.
  • Rani Therapeutics Holdings' Short term Debt stood at $126000.0 in 2021, then tumbled by 56.35% to $55000.0 in 2022, then skyrocketed by 8803.64% to $4.9 million in 2023, then skyrocketed by 206.31% to $15.0 million in 2024, then dropped by 9.75% to $13.5 million in 2025.
  • The last three reported values for Short term Debt were $13.5 million (Q3 2025), $15.0 million (Q2 2025), and $15.0 million (Q1 2025) per Business Quant data.